Kaléo Announces Theresa Matkovits, Ph.D. as Chief Development Officer
29. Oktober 2024 08:00 ET
|
Kaléo
Richmond, Virginia, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Kaléo, a fully integrated pharmaceutical company dedicated to inventing, manufacturing, and commercializing life-transforming products, today...
Kaléo Redesigns Commercial Team to Increase Support for AUVI-Q® (epinephrine injection, USP)
01. Oktober 2024 08:00 ET
|
Kaléo
Richmond, Virginia, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Kaléo, a privately-held U.S. pharmaceutical company has announced a redesign of the AUVI-Q® (epinephrine injection, USP) commercial team structure...
U.S. Department of Health and Human Services Awards Kaléo with Contract to Develop Next Generation Organophosphate Nerve Agent Poisoning Countermeasure
17. April 2024 08:00 ET
|
Kaléo
Richmond, Virginia, April 17, 2024 (GLOBE NEWSWIRE) -- Kaléo, a privately-held U.S. pharmaceutical company today announced their selection by the Biomedical Advanced Research and Development...
U.S. Department of Defense Selects Kaléo to Develop Next Generation Nerve Agent Countermeasure
18. Juli 2023 08:00 ET
|
Kaléo
Richmond, Virginia, July 18, 2023 (GLOBE NEWSWIRE) -- Kaléo, a privately-held U.S. pharmaceutical company, today announced their selection by the U.S. Department of Defense (DOD) Joint Program...
Kaléo Expands Executive Team to Support Growth
27. Juni 2023 08:00 ET
|
Kaléo
Richmond, VA, June 27, 2023 (GLOBE NEWSWIRE) -- Kaléo, a fully integrated pharmaceutical company dedicated to creating innovative healthcare solutions to protect and empower patients, today...
Kaléo Expands Executive Team to Support Growth
27. Juni 2023 08:00 ET
|
Kaléo
Richmond, VA, June 27, 2023 (GLOBE NEWSWIRE) -- Kaléo, a fully integrated pharmaceutical company dedicated to creating innovative healthcare solutions to protect and empower patients, today...
Kaléo Announces Appointment of Major General Elder Granger, M.D., to Board
25. Oktober 2022 08:00 ET
|
Kaléo
Richmond, Virginia, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Kaléo, a fully integrated pharmaceutical company dedicated to inventing, manufacturing, and commercializing life-transforming products, today...
Kaléo Adds Chief Business Officer to Executive Team
27. September 2022 08:00 ET
|
Kaléo
Richmond, VA, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Kaléo, a fully integrated pharmaceutical company dedicated to inventing, manufacturing, and commercializing life-transforming products, today...
Kaléo Announces First U.S. Department of Defense Supply Contract for the Rapid Opioid Countermeasure System (ROCS) Antidote for Ultra-Potent Weaponized Opioids
21. September 2022 08:00 ET
|
Kaléo
Richmond, VA, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Kaléo, a privately held commercial-stage U.S. pharmaceutical company, today announced the execution of the first contract with the U.S. Department of...
Kaléo Announces Executive Appointments and New Government Business Unit
11. August 2022 08:25 ET
|
Kaléo
Richmond, VA, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Kaléo, a fully integrated pharmaceutical company dedicated to inventing, manufacturing, and commercializing life-transforming products for certain...